Literature DB >> 2291672

Loracarbef concentrations in middle ear fluid.

H Kusmiesz1, S Shelton, O Brown, S Manning, J D Nelson.   

Abstract

Loracarbef concentrations in plasma and middle ear fluid (MEF) were measured in specimens obtained approximately 2 h after doses of 7.5 or 15 mg/kg. The mean +/- standard deviation concentrations in MEF were 2.0 +/- 2.6 mg/liter (48% of the concentration in plasma) after the smaller dose and 3.9 +/- 2.6 mg/liter (42% of the concentration in plasma) after the larger dose. With the larger dose, the concentrations in MEF were greater than the MIC for 90% of strains of the usual pathogens of acute otitis media tested in 16 of 17 specimens.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2291672      PMCID： PMC171986          DOI： 10.1128/AAC.34.10.2030

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  4 in total

1.  In vitro susceptibilities of common pediatric pathogens to LY163892.

Authors:  S Shelton; J D Nelson
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

2.  Concentrations of antimicrobial agents in middle ear fluid, saliva and tears.

Authors:  J D Nelson; C M Ginsburg; O Mcleland; J Clahsen; M C Culbertson; H Carder
Journal:  Int J Pediatr Otorhinolaryngol       Date:  1981-12       Impact factor: 1.675

3.  Pharmacokinetics of LY163892 in infants and children.

Authors:  J D Nelson; S Shelton; H Kusmiesz
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

4.  Penetration of amoxicillin, cefaclor, erythromycin-sulfisoxazole, and trimethoprim-sulfamethoxazole into the middle ear fluid of patients with chronic serous otitis media.

Authors:  P J Krause; N J Owens; C H Nightingale; J J Klimek; W B Lehmann; R Quintiliani
Journal:  J Infect Dis       Date:  1982-06       Impact factor: 5.226
  4 in total
  6 in total

1.  Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model.

Authors:  D M Cappelletty; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

2.  Pharmaceutical properties of loracarbef: the remarkable solution stability of an oral 1-carba-1-dethiacephalosporin antibiotic.

Authors:  C E Pasini; J M Indelicato
Journal:  Pharm Res       Date:  1992-02       Impact factor: 4.200

3.  Bactericidal titers of loracarbef (LY 163892) in serum and killing rates in volunteers receiving 400 versus 200 milligrams.

Authors:  P Van der Auwera
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

Review 4.  Loracarbef. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D McTavish
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

6.  In vitro activities of oral beta-lactams at concentrations achieved in humans against penicillin-susceptible and -resistant pneumococci and potential to select resistance.

Authors:  C E Thorburn; S J Knott; D I Edwards
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.